REFERENCES

Beeton N, McCallum H (2011) Models predict that culling is not a feasible strategy to prevent extinction of Tasmanian devils from facial tumour disease. Journal of Applied Ecology 48, 1315-1323.

Belov K (2011) The role of the Major Histocompatibility Complex in the spread of contagious cancers. Mammalian Genome 22, 83-90. doi:10.1007/s00335-010-9294-2

Belov K (2012) Contagious cancer: lessons from the devil and the dog. BioEssays 34, 285-292. doi:10.1002/bies.201100161

Bender HS, Graves JM, Deakin JE (2014) Pathogenesis and molecular biology of a transmissible tumor in the Tasmanian Devil. Annual Review of Animal Biosciences 2, 165-187. doi:10.1146/annurev- animal-022513-114204

Brown GK, Kreiss A, Lyons AB, Woods GM (2011) Natural killer cell mediated cytotoxic responses in the Tasmanian Devil. PLoS One 6, e24475. doi:10.1371/journal.pone.0024475

Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, Corcoran LM, Bettiol SS, Lyons AB, Woods GM (2016) Mitogen- activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells. Immunology and Cell Biology 94, 673-679. doi:10.1038/icb.2016.38

Cunningham CX, Comte S, McCallum H, Hamilton DG, Hamede R, Storfer A, Hollings T, Ruiz-Aravena M, Kerlin DH, Brook BW, Hocking G, Jones ME (2021) Quantifying 25 years of disease-caused declines in Tasmanian devil populations: host density drives spatial pathogen spread. Ecology Letters 24, 958-969. doi:10.1111/ele.13703 Deakin JE, Belov K (2012) A comparative genomics approach to under­standing transmissible cancer in Tasmanian Devils. In Annual Review of Genomics and Human Genetics, Vol 13. (Eds A Chakravarti and E Green) pp. 207-222. Annual Reviews, Palo Alto, CA.

Dempsey S, Pye RJ, Gilbert AT, Fountain-Jones NM, Moffat JM, Ben- son-Amram S, Smyer TJ, Flies AS (2023) Evaluation of oral baits and distribution methods for Tasmanian devils (Sarcophilus harrisii).

Drawert B, Flies AS, Mathew S, Powell M, Rumsey B (2022) Saving the Devils is in the details: Tasmanian Devil Facial Tumour Disease can be eliminated with interventions. Letters in Biomathematics 9, 121-140. doi:10.30707/LiB9.1.1681913305.269822

Espejo C, Wilson R, Pye RJ, Ratcliffe JC, Ruiz-Aravena M, Willms E, Wolfe BW, Hamede R, Hill AF, Jonmes ME, Woods GM, Lyons B (2022) Cathelicidin-3 associated with serum extracellular vesicles enables early diagnosis of a transmissible cancer. Frontiers of Immunology 13, 858423. doi:10.1101/2021.12.06.471373

Gathercole JL (2012) Biomarker discovery for pre-clinical diagnosis of Tasmanian devil facial tumour disease. PhD thesis. University of Tasmania, Hobart.

Grueber CE, Peel E, Gooley R, Belov K (2015) Genomic insights into a contagious cancer in Tasmanian devils. Trends in Genetics 31, 528-535. doi:10.1016/j.tig.2015.05.001

Hamede R, Bashford J, Jones M, McCallum H (2012a) Simulating devil facial tumour disease outbreaks across empirically derived contact networks. Journal of Applied Ecology 49, 447-456. doi:10.1111/ j.1365-2664.2011.02103.x

Hamede R, Lachish S, Belov K, Woods G, Kreiss A, Pearse AM, Lazenby B, Jones M, McCallum H (2012b) Reduced effect of Tasmanian devil facial tumor disease at the disease front. Conservation Biology 26, 124-134. doi:10.1111/j.1523-1739.2011.01747.x

Hamede RK, McCallum H, Jones M (2013) Biting injuries and trans­mission of Tasmanian devil facial tumour disease. Journal of Animal Ecology 82, 182-190. doi:10.1111/j.1365-2656.2012.02025.x Hamede R, Fountain-Jones NM, Arce F, Jones M, Storfer A, Hohenlohe PA, McCallum H, Roche B, Ujvari B, Thomas F (2023) The tumour is in the detail: local phylogenetic, population and epidemiological dynamics of a transmissible cancer in Tasmanian devils. Evolution­ary Applications 16, 1316-1327. doi:10.1111/eva.13569

Hawkins CE, Baars C, Hesterman H, Hocking GJ, Jones ME, Lazenby B, Mann D, Mooney N, Pemberton D, Pyecroft S, Restani M, Wiersma J (2006) Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii.

Hayes DA (2019) Further immunohistochemical (IHC) characterisa­tion of devil facial tumour disease 1 (DFT1) in the Tasmanian Devil (Sarcophilus harrisii). University of Tasmania. Thesis. doi:10.25959/100.00031712

Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET (2017) ERBB3: a potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One 12, e0177919. doi:10.1371/journal.pone.0177919

Holz P (2008) Dasyurids. In Medicine of Australian Mammals. (Eds L Vogelnest and R Woods) pp. 359-382. CSIRO Publishing, Melbourne.

Jones ME, McCallum H (2011) The devil’s cancer. Scientific American 304, 72-77. doi:10.1038/scientificamerican0611-72

Karu N, Wilson R, Hamede R, Jones M, Woods GM, Hilder EF, Shellie RA (2016) Discovery of biomarkers for Tasmanian devil cancer (DFTD) by metabolic profiling of serum. Journal of Proteome Research 15, 3827-3840. doi:10.1021/acs.jproteome.6b00629

Kozakiewicz CP, Ricci L, Patton AH, Stahlke AR, Hendricks SA, Margres MJ, Ruiz-Aravena M, Hamilton DG, Hamede R, McCallum H, Jone ME, Hohenlohe PA, Storfer A (2020) Compara­tive landscape genetics reveals differential effects of environment on host and pathogen genetic structure in Tasmanian devils (Sarco- philus harrisii) and their transmissible tumour. Molecular Ecology 29, 3217-3233. doi:10.1111/mec.15558

Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM (2008) Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Developmental and Com­parative Immunology 32, 544-553. doi:10.1016/j.dci.2007.09.002

Kreiss A, Cheng YY, Kimble F, Wells B, Donovan S, Belov K, Woods GM (2011a) Allorecognition in the Tasmanian Devil (Sarcophi- lus harrisii), an endangered marsupial species with limited genetic diversity. PLoS One 6, e22402. doi:10.1371/journal. pone.0022402

Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM (2011b) A murine xenograft model for a transmissible cancer in Tasmanian devils.

Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM (2015) Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Vaccine 33, 3016-3025. doi:10.1016/j.vaccine.2015.01.039

Lachish S, McCallum H, Mann D, Pukk CE, Jones ME (2010) Evalua­tion of selective culling of infected individuals to control Tasma­nian devil facial tumor disease. Conservation Biology 24, 841-851. doi:10.1111/j.1523-1739.2009.01429.x

Lazenby BT, Tobler MW, Brown WE, Hawkins CE, Hocking GE, Hume F, Huxtable S, Iles P, Jones ME, Lawrence C, Thalmann S, Wise P, Williams H, Fox S, Pemberton D (2018) Density trends and demo­graphic signals uncover the long-term impact of transmissible cancer in Tasmanian devils. Journal of Applied Ecology 55, 1368-1379.

Loh R, Bergfeld J, Hayes D, O’Hara A, Pyecroft S, Raidal S, Sharpe R (2006a) The pathology of devil facial tumour disease (DFTD) in Tasmanian Devils (Sarcophilus harrisii). Veterinary Pathology 43, 890-895.

Loh R, Hayes D, Mahjoor A, O’Hara A, Pyecroft S, Raidal S (2006b) The immunohistochemical characterization of devil facial tumor disease (DFTD) in the Tasmanian Devil (Sarcophilus harrisii). Vet­erinary Pathology 43, 896-903.

McCallum H, Tompkins DM, Jones M, Lachish S, Marvanek S, Lazenby B, Hocking G, Wiersma J, Hawkins CE (2007) Distribution and impacts of Tasmanian devil facial tumor disease. EcoHealth 4, 318-325. doi:10.1007/s10393-007-0118-0

Metzger MJ, Goff SP (2016) A sixth modality of infectious disease: contagious cancer from Devils to clams and beyond. PLoS Patho­gens 12, e1005904. doi:10.1371/journal.ppat.1005904

Morris K, Belov K (2013) Does the devil facial tumour produce immu­nosuppressive cytokines as an immune evasion strategy? Veteri­nary Immunology and Immunopathology 153, 159-164. doi:10. 1016/j.vetimm.2013.02.008.

Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, Kreiss A, Kellis M, Stark A, Harkins TT, Graves JAM, Woods GM, Hannon GJ, Papenfuss AT (2010) The Tasmanian Devil transcrip­tome reveals Schwann cell origins of a clonally transmissible cancer. Science 327, 84-87. doi:10.1126/science.1180616

Murchison EP, Schulz-Trieglaff OB, Ning ZM, Alexandrov LB, Bauer MJ, Fu BY, Hims M, Ding ZH, Ivakhno S, Stewart C, Ng BL, Wong WD, Aken B, White S, Alsop A, Becq J, Bignell GR, Cheetham RK, Cheng W, Connor TR, Cox AJ, Feng ZP, Gu Y, Grocock RJ, Harris SR, Khrebtukova I, Kingsbury Z, Kowarsky M, Kreiss A, Luo SJ, Marshall J, McBride DJ, Murray L, Pearse AM, Raine K, Rasolon- jatovo I, Shaw R, Tedder P, Tregidgo C, Vilella AJ, Wedge DC, Woods GM, Gormley N, Humphray S, Schroth G, Smith G, Hall K, Searle SMJ, Carter NP, Papenfuss AT, Futreal PA, Campbell PJ, Yang FT, Bentley DR, Evers DJ, Stratton MR (2012) Genome sequencing and analysis of the Tasmanian Devil and its transmis­sible cancer. Cell 148, 780-791. doi:10.1016/j.cell.2011.11.065

Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM (2016) The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines. PLoS One 11, e0168068. doi:10.1371/ journal.pone.0168068

Pearse A-M, Swift K (2006) Allograft theory: transmission of devil facial-tumour disease. Nature 439, 549.

Pearse A-M, Swift K, Hodson P, Hua B, McCallum H, Pyecroft S, Taylor R, Eldridge MDB, Belov K (2012) Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population. Cancer Genetics 205, 101-112. doi:10.1016/j.cancergen.2011.12.001

Peck S, Corkrey R, Hamede R, Jones M, Canfield P (2015) Hematologic and serum biochemical reference intervals for wild Tasmanian devils (Sarcophilus harrisii). Veterinary Clinical Pathology 44, 519-529. doi:10.1111/vcp.12304

Peck S, Corkrey R, Hamede R, Jones M, Canfield P (2016) Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils.

Phalen DN, Frimberger A, Pyecroft S, Peck S, Harmsen C, Lola S, de Mello Mattos B, Li KM, McLachlan AJ, Moore A (2013) Vincristine chemotherapy trials and pharmacokinetics in Tasmanian devils with Tasmanian devil facial tumor disease. PLoS One 8, e65133. doi:10.1371/journal.pone.0065133

Phalen DN, Frimberger AE, Peck S, Pyecroft S, Harmsen C, Lola S, Moore AS (2015) Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease. Veterinary Journal (London, England) 206, 312-316. doi:10.1016/j.tvjl.2015.10.013

Pinfold TL, Brown GK, Bettiol SS, Woods GM (2014) Mouse model of devil facial tumour disease establishes that an effective immune response can be generated against the cancer cells. Frontiers in Immunology 5, 251.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM (2016a) Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Biology Letters 12, 20160553. doi:10.1098/rsbl.2016.0553

Pye RJ, Pemberton D, Tovar C, Tubio JMC, Dun KA, Fox S, Darby J, Hayes D, Knowles GW, Kreiss A, Siddle HVT, Swift K, Lyons AB, Murchison EP, Woods GM (2016b) A second transmissible cancer in Tasmanian devils. Proceedings of the National Academy of Sciences of the United States of America 113, 374-379. doi:10.1073/ pnas.1519691113

Pye RJ, Woods GM, Kreiss A (2016c) Devil facial tumor disease. Veteri­nary Pathology 53, 726-736. doi:10.1177/0300985815616444

Pye R, Darby J, Flies AS, Fox S, Carver S, Elmer J, Swift K, Hogg, Pem­berton D, Woods G, Lyons B (2021) Post-release immune responses in Tasmanian devils vaccinated with an experimental devil facial tumour disease vaccine. Wildlife Research 48, 701-712. doi:10.1071/ WR20210

Pyecroft SB, Pearse AM, Loh R, Swift K, Belov K, Fox N, Noonan E, Hayes D, Hyatt A, Wang L, Boyle D, Church J, Middleton D, Moore R (2007) Towards a case definition for devil facial tumour disease: what is it? EcoHealth 4, 346-351. doi:10.1007/s10393-007-0126-0

Stammnitz MR, Gori K, Mi Kwon Y, Harry E, Martin FJ, Billis K, Cheng Y, Baez-Ortega A, Chow W, Comte S, Eggertsson H, Fox S, Hamede R, Jones M, Lazenby B, Peck S, Pye R, Qual MA, Swift K, Wang J, Wood J, Howe K, Stratton MR, Ning Z, Murchison EP (2023) Thie evolution of two transmissible cancers in Tasmanian devils. Science 380, 283-293. doi:10.1126/science.abq6453

Tovar C, Obendorf D, Murchison EP, Papenfuss AT, Kreiss A, Woods GM (2011) Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies. Veterinary Pathology 48, 1195-1203. doi:10.1177/0300985811400447 Tovar C, Pye RJ, Kreiss A, Cheng YY, Brown GK, Darby J, Malley RC, Siddle HVT, Skjodt K, Kaufman J, Silva A, Morelli AB, Papenfuss AT, Corcoran LM, Murphy JM, Pearse MJ, Belov K, Lyons AB, Woods GM (2017) Regression of devil facial tumour disease follow­ing immunotherapy in immunised Tasmanian devils. Scientific Reports 7, 43827. doi:10.1038/srep43827

Wells K, Hamede RK, Kerlin DH, Storfer A, Hohenlohe PA, Jones ME, McCallum HI (2017) Infection of the fittest: devil facial tumour disease has greatest effect on individuals with highest reproductive output. Ecology Letters 20, 770-778. doi:10.1111/ ele.12776

Wright B, Willet CE, Hamede R, Jones M, Belov K, Wade CM (2017) Variants in the host genome may inhibit tumour growth in devil facial tumours: evidence from genomewide association. Scientific Reports 7, 423. doi:10.1038/s41598-017-00439-7

41